CLINICAL_TRIALS
trial_result
· 2026-01-13
Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) [Phase 3]
Summary
PATHFNDR-2 is a Phase 3 study assessing the safety and efficacy of Paltusotine for acromegaly. Results were posted on January 13, 2026.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Crinetics Pharmaceuticals Inc. | Conditions: Acromegaly | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-13